{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-222890","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2026-05-14T12:15:14+00:00","discovered_at":"2026-05-14T12:20:00.440663+00:00","generated_at":"2026-05-14T12:24:51.478537+00:00","sec_items":["5.02","5.07","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Corbus appoints Brent Pfeiffenberger to board; shareholders approve 3M share increase for equity plan","bullets":["Appointed Brent Pfeiffenberger (CEO Century Therapeutics, former SVP BMS) to board, expanding to 7 members.","Stockholders approved amendment to 2024 Equity Plan increasing authorized shares by 3M to total 5M shares.","All six director nominees elected; advisory say-on-pay approved with 92% of votes cast in favor.","CRB-701 Nectin-4 ADC data at ASCO 2026; FDA alignment on registration path for HNSCC; registrational study this summer.","CANYON-1 Phase 1b study for CRB-913 (CB1 inverse agonist) on track to complete summer 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-222890","json":"https://secwatch.observer/filing/0001193125-26-222890.json","markdown":"https://secwatch.observer/filing/0001193125-26-222890.md","text":"https://secwatch.observer/filing/0001193125-26-222890.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526222890/0001193125-26-222890-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526222890/crbp-20260513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T12:24:51.478537+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a38bbbb85","claim":"Brent Pfeiffenberger was appointed as director at Corbus Pharmaceuticals Holdings, Inc..","evidence_excerpt":"On May 13, 2026, the board of directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Brent Pfeiffenberger, age 48, to serve as a member of the Board, thereby expanding the Board to seven members.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526222890/0001193125-26-222890-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}